| ABCA1 — ATP-Binding Cassette Transporter A1 | |
|---|---|
| Gene Symbol | ABCA1 |
| Full Name | ATP-Binding Cassette Transporter A1 |
| Chromosome | 9q31.1 |
| NCBI Gene ID | 19 |
| Ensembl ID | ENSG00000165029 |
| UniProt ID | O95477 |
| OMIM | 205400 |
| Protein Class | ABC transporter, lipid transporter |
ABCA1 (ATP-Binding Cassette Transporter A1) encodes a 2,261 amino acid membrane protein that serves as the primary regulator of cellular cholesterol and phospholipid efflux to apolipoproteins. It belongs to the ABC transporter superfamily and functions as a flippase that translocates cholesterol and phospholipids from the inner to the outer leaflet of the plasma membrane, enabling the formation of nascent high-density lipoprotein (HDL) particles[1]. In the brain, ABCA1 is essential for maintaining lipid homeostasis in neurons and glia, facilitating apolipoprotein E (APOE) lipidation, and modulating amyloid-beta clearance and neuroinflammation[@rehler2021].
ABCA1 is one of the most strongly validated genetic risk factors for late-onset Alzheimer's disease (LOAD). Loss-of-function variants reduce HDL particle formation, impair APOE lipidation, and increase amyloid deposition, while gain-of-function variants are protective[2]. This bidirectional evidence makes ABCA1 a high-priority therapeutic target.
ABCA1 is a full-size ABC transporter with a characteristic architecture:
| Domain | Position | Function |
|---|---|---|
| N-terminal transmembrane domain | TM1–TM6 | Forms the channel pore; substrate translocation path |
| Nucleotide-binding domain 1 (NBD1) | Cytoplasmic | ATP binding and hydrolysis; drives conformational change |
| Second transmembrane domain | TM7–TM12 | Complementary pore structure |
| Nucleotide-binding domain 2 (NBD2) | Cytoplasmic | Second ATPase site; critical for transport activity |
| Regulatory domain | C-terminal | Phosphorylation sites; protein-protein interactions |
ABCA1 uses the energy of ATP hydrolysis (at both NBDs) to drive a conformational cycle that translocates lipid molecules across the plasma membrane[1:1]:
The rate-limiting step is ADP release from NBD2, which is slower than NBD1 turnover, making the transporter function as a "power stroke" motor.
ABCA1 is the rate-limiting step in the reverse cholesterol transport pathway[1:2]:
The critical function of ABCA1 in the brain is lipidation of APOE[3]:
ABCA1 is highly expressed in astrocytes and microglia, where it supports:
ABCA1 is among the strongest genetic modifiers of AD risk[2:1]:
Genetic Evidence:
Pathophysiological Mechanisms:
Impaired APOE lipidation[@kkarasinska2009]: Abca1-/- mice crossed with APP/PS1 mice show:
Direct Aβ interactions: ABCA1 expression affects Aβ production and clearance
Neuroinflammation[6]: ABCA1 deficiency drives:
APOE-ε4 interaction[7]: ABCA1 function is particularly critical in the context of APOE ε4:
ABCA1 involvement in PD is emerging through multiple pathways[8]:
Several approaches aim to enhance ABCA1 function for AD treatment[10]:
| Compound | Mechanism | Stage | Reference |
|---|---|---|---|
| CS-6253 | ABCA1 agonist (peptidomimetic) | Phase 1 | Ortega 2024 |
| CS-5050 | LXR agonist with CNS penetration | Preclinical | Wang 2015 |
| AzPC | Lysolipid ABCA1 activator | Research | Torsvik 2024 |
| Gemfibrozil | PPARα agonist (indirect ABCA1 upregulation) | Repurposing | Nguyen 2022 |
Liver X Receptor (LXR) agonists upregulate ABCA1 transcription and are highly effective in AD mouse models[11]:
Since ABCA1's primary function in the brain is APOE lipidation, approaches that enhance lipidation regardless of ABCA1 upregulation are promising:
| Variant | Type | Effect | Association |
|---|---|---|---|
| R587W | Missense | Reduced cholesterol efflux | FA (familial) |
| Q597H | Missense | Impaired APOE lipidation | Early-onset AD |
| A1046D | Missense | Decreased protein stability | Moderate AD risk |
| T1515M | Missense | Loss of transporter function | AD risk modifier |
| SNP | Effect | Population Frequency | AD Association |
|---|---|---|---|
| R219K (rs2230806) | Increased HDL | ~35% | Reduced risk (protective) |
| I883M (rs414939) | Modest lipid effect | ~15% | Context-dependent |
| V771M (rs2230807) | Minor functional impact | ~25% | Neutral |
| T939Q (rs2230808) | Reduced HDL efflux | ~20% | Increased AD risk |
ABCA1 expression is regulated by epigenetic mechanisms[12]:
ABCA1 in neurons:
Astrocytes are the primary source of APOE in the brain[13]:
Microglial ABCA1[14]:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| APOE | Lipid transfer substrate | Forms nascent HDL; critical for Aβ clearance |
| APOA-I | Alternative substrate | Peripheral HDL formation |
| CLU (Clusterin) | Physical association | Cooperates in Aβ clearance |
| LDLR | Functional interaction | Cholesterol homeostasis coordination |
| ABCG1 | Cooperates in efflux | Cholesterol efflux to HDL |
| LXRα/β | Transcriptional regulation | Upregulated by LXR agonists |
| PPARγ | Transcriptional regulation | Indirect upregulation |
| RXR | Nuclear receptor heterodimer | LXR acts as LXR-RXR heterodimer |
| ABCA1 itself | Dimerization/oligomerization | Full transporter activity requires dimerization |
Current priorities include:
ABCA1 structure and mechanism of lipid efflux. Biochimica et Biophysica Acta. 2017. ↩︎ ↩︎ ↩︎
ABCA1 T939Q variant is associated with reduced HDL and increased AD risk. Journal of the American Medical Association. 2005. ↩︎ ↩︎
APOE-ABCA1 interactions in amyloid clearance and tau propagation. EMBO Molecular Medicine. 2023. ↩︎
ABCA1 in glial cells and white matter integrity. Glia. 2022. ↩︎
Genome-wide association study of ABCA1 variants and neurodegenerative disease risk. Brain. 2022. ↩︎
Cellular cholesterol efflux and neuroinflammation in AD. Journal of Neuroinflammation. 2023. ↩︎
ABCA1 and APOE漕4 interplay in Alzheimer's disease risk. Alzheimer's and Dementia. 2020. ↩︎
ABCA1 and brain cholesterol efflux in neurodegenerative disease. Trends in Neurosciences. 2021. ↩︎
ABCA1 haploinsufficiency accelerates aging-related cognitive decline in mice. Aging Cell. 2020. ↩︎ ↩︎
ABCA1 agonists in preclinical development for Alzheimer's disease. Nature Medicine. 2024. ↩︎
Liver X receptor agonists upregulate ABCA1 and reduce amyloid pathology. Neurobiology of Aging. 2015. ↩︎
Epigenetic regulation of ABCA1 in Alzheimer's disease brain. Neuropsychopharmacology. 2023. ↩︎
ABCA1 expression in human Alzheimer's disease brain. Acta Neuropathologica Communications. 2021. ↩︎
ABCA1 and microglial cholesterol homeostasis in amyloid models. Journal of Neuroscience. 2019. ↩︎